Business Wire

INMARSAT

23.5.2023 09:01:35 CEST | Business Wire | Press release

Share
Inmarsat’s Fastest Ever Inflight Broadband Plans Are Now Available for Business Aviation Customers

Inmarsat has announced the next chapter of its market-leading Jet ConneX (JX) inflight broadband solution, with a new range of service plans introduced to redefine gold standard connectivity in the business aviation market and satisfy even the most data-hungry users for many years to come.

Launched as part of Inmarsat’s JX Evolution programme, these latest service plans are available for new and existing customers to order today, marking a step-change in performance that is backed by guaranteed speeds and Inmarsat’s hallmark consistent customer experience.

The new service plans offer enhanced performance using Jet ConneX’s existing, highly successful JetWave terminal by Inmarsat’s partner Honeywell, and will also be compatible with three upcoming next-generation terminals being developed by Satcom Direct, Orbit and Honeywell. Satcom Direct’s Plane Simple Ka-band system has commenced flight testing and is expected to enter service later this year.

All three next-generation terminals use innovative technology and lightweight designs to optimise performance, reduce costs, and simplify installation and maintenance. Their reduced size and weight make them suitable for various types of business jets, creating new opportunities in the fast-growing super midsize aircraft market, which shares many of the same connectivity requirements as large aircraft.

Jet ConneX customers will also benefit from seven more Inmarsat satellite payloads entering service by 2025, increasing its Ka-band network fleet to 12. This includes two Inmarsat-6s, both of which have already launched, followed by two payloads in highly elliptical orbit, enabling the world’s only commercial mobile broadband service for flights in higher latitudes and across the Arctic. Three additional satellites will then launch in geostationary orbit, adding further speed, capacity, and resilience.

The combination of next generation terminals and Inmarsat’s fast-growing satellite network will enable speeds up to 100 Mbps, for top tier customers that demand the highest level ‘office-in-the-sky’ experience.

The new Jet ConneX service plans are available through Inmarsat’s global business aviation distribution network, which consists of Satcom Direct, Collins Aerospace and Honeywell.

Kai Tang, Inmarsat’s Head of Business Aviation, said “Jet ConneX is renowned for delivering a very high standard of service and these transformative new plans once again highlight Inmarsat’s continued focus on staying ahead of market expectations. This provides customers with reassurance that our connectivity will keep pace with their long-term needs. Importantly, as these include the first plans to use our new satellites and terminals, it also offers a glimpse into future capabilities and provides certainty that their investment in our technology is future-proofed.

“These service plans have been specifically designed to deliver even greater value and performance based on unique insights into usage of our inflight broadband service. This build-up approach is unique to Inmarsat and cannot be replicated by others in the market, some of which have a tendency to over promise and under deliver, either from the start or as their networks fill and performance degrades.

“Crucially, this is only the next step for us. We will continue to assess usage and adapt accordingly, with even more flexible options to be announced later this year.”

Since entering commercial service in November 2016, Jet ConneX has been activated on more than 1,400 business jets: offering the same reliable, consistent and high-speed broadband that was previously only available on the ground. Passenger usage of Jet ConneX increased to record levels since the pandemic, testament to fast-growing expectations from users, who use everything from video streaming and live TV to conference calls and other business activities. JX’s most powerful service plans will now enable passengers to simultaneously connect more devices and enjoy unchallenged access to the most data-hungry applications - including high-definition video conferencing - without compromising on its proven characteristics of consistency, reliability, resilience, and seamless global availability.

Inmarsat’s 2023 global survey of business aviation professionals - conducted in partnership with Corporate Jet Investor (CJI) - found that 82% of respondents believe inflight connectivity has evolved from a luxury option for some, to a key requirement for the majority of passengers. The results, published at the European Business Aviation Convention & Exhibition (EBACE) this week, show the three most important factors when selecting a connectivity system, in order, were consistent performance, 100% route coverage, and high speed.

ENDS

ABOUT INMARSAT
Inmarsat delivers world leading, innovative, advanced and exceptionally reliable global, mobile communications across the world – in the air, at sea and on land - that are enabling a new generation of commercial, government and mission-critical services. Inmarsat is powering the digitalisation of the maritime industry, making operations more efficient and safer than ever before. It is driving a new era of inflight passenger services for aviation, while ensuring that aircraft can fly with maximum efficiency and safety. Furthermore, Inmarsat is enabling the rapid expansion of the Internet of Things (IoT) and enabling the next wave of world-changing technologies that will underpin the connected society and help build a sustainable future. And now Inmarsat is developing the first-of-its-kind, multi-dimensional communications network of the future, ORCHESTRA.

In November 2021, Inmarsat and Viasat announced the planned combination of the two companies, to create a new leader in global communications.

For further information, follow us: Twitter | LinkedIn | Facebook | YouTube | Instagram.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230523005098/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye